Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemakerThe study successfully met... | May 20, 2023

Related Keywords

Canada ,United States ,Netherlands ,Amsterdam ,Noord Holland ,Randel Woodgrift ,Reinoude Knops ,Twitter ,Amsterdam University Medical Center ,Linkedin ,Facebook ,Drug Administration ,Heart Rhythm Society ,Investigational Device Exemption ,New Orleans ,New England Journal ,Breaking Data ,Abbott Laboratories Stock Exchange ,News ,Information ,Press Release ,Dr ,Dude ,Study ,Us ,The ,First ,Prospective ,N ,Safety ,End ,Performance ,F ,Hheadless ,Acemakerthe ,Uccessfully Abt Us0028241000 ,